Also in the context of breast cancer in recent years, the use of Nutlin-3 was preclinically validated in combination with (i) carboplatin, in a humanized orthotropic breast-to-lung metastatic model [72] and (ii) paclitaxel, against aggressive diseases such as triple-negative and Numb-deficient human breast cancers [73, 74]. The gene discussed is NUMB; the disease is breast cancer.